NAFDAC ALERTS PUBLIC TO SUSPECTED COUNTERFEIT FORXIGA MEDICINES IN CIRCULATION. (PHOTO).
NAFDAC Alerts Public to Suspected Counterfeit Forxiga Medicines in Circulation The National Agency for Food and Drug Administration and Control (NAFDAC) has alerted the public to the circulation of suspected counterfeit medicinal products mimicking Forxiga (dapagliflozin) in the Nigerian market, warning that their use could pose serious health risks. The agency said the suspected counterfeit products were detected following market surveillance by pharmaceutical company AstraZeneca. The disclosure was contained in Public Alert No. 036/2026 posted on NAFDAC’s X handle on Thursday. According to the notice, AstraZeneca notified the agency after identifying products bearing names closely resembling Forxiga® and imitating the company’s brand identity and logo. Genuine Forxiga® (dapagliflozin) is prescribed to improve blood sugar control in people with Type 2 diabetes, reduce cardiovascular deaths and hospitalisations in patients with heart failure, and slow the progression of chronic ki...

Comments
Post a Comment